The pipeline in retina is bursting! Which datasets shared at the ASRS 2021 meeting provided insights into the future of retina? Mark Barakat, MD, joins the podcast to discuss topline results from a study examining the suprachoroidal delivery of RGX-314 (RegenxBio). And Nancy Holekamp, MD, stops by to educate us on the potential for targeting C1q in the complement cascade in patients with geographic atrophy. What’s the latest with the phase 2 ARCHER study? Find out on this episode.

This editorially independent podcast is supported with advertising.

The age of big data allows researchers to uncover how real-world patients with geographic atrophy (GA) behave. What did a deep dive into the IRIS Registry find? We spoke with Durga Borkar, MD, about her research team’s findings on which GA patients are most at risk to being lost to follow-up, which may inform treatment strategies once a drug is approved. And we sat down with M. Ali Khan, MD, whose meta-analysis of RISE/RIDE and three DRCR Retina Network studies explored possible visual outcomes gaps in Black and White patients with diabetic eye disease. 

This editorially independent podcast is supported with advertising.

We may be on the cusp of the next great era of wet AMD therapy. Which phase 3 data will guide physician decision-making if new technologies are approved by regulatory bodies? Chirag Jhaveri, MD, spoke with New Retina Radio about anatomic data collected in the phase 3 ARCHWAY study. How did patients who received the Port Delivery System with Ranibizumab (PDS, Genentech) differ from those on monthly ranibizumab (Lucentis, Genentech) in terms of fluctuation in central subfield thickness? And as FDA weighs the possible approval of faricimab for the treatment of wet AMD, we hear from Karl Csaky, MD, PhD, about the safety, efficacy, and durability of the drug for wet AMD in the TENAYA and LUCERNE studies. 

This editorially independent podcast is supported with advertising.

How can retina surgeons work with optometrists to create a framework that best manages the cases of patients with vitreous opacities? To answer this question, John Kitchens, MD, turns to Tarek Hassan, MD, and Walt Whitley, OD, MBA. The panel discusses how collaboration can transition patients smoothly to surgical consultation, the anatomy of a referral, and if some patients are better suited for surgery than others. 

This editorially independent podcast is supported with advertising.

Cytomegalovirus (CMV) retinitis continues to challenge retina specialists. Could use of CMV-specific cytotoxic T lymphocytes be an effective strategy in some patients? And if so, in whom? To answer these questions, Christina Weng, MD, MBA, is joined by study author Mrinali Gupta, MD, and panelists Brian Do, MD, and Dimitra Skondra, MD, PhD. During their discussion, we hear about the structure and findings of the study and learn about how these new data may affect treatment algorithms for patients with newly diagnosed CMV retinitis. 

This editorially independent podcast is supported with advertising.

In the next installment of the New Retina Radio miniseries "International Perspectives," moderator Jennifer Arnold (Australia) in joined by panelists Ramin Tadayoni (France) and Armin Wolf (Germany) to discuss the history and contemporary trends of RVO therapy. 

This editorially independent podcast is supported with advertising.

It isn't often that anterior segment and posterior segment surgeons discuss surgery. New Retina Radio, in a crossover episode with CRST: The Podcast, is changing that by initiating a conversation about surgery for vitreous opacities. John Kitchens, MD, invites retina specialist Maria Berrocal, MD, and anterior segment surgeon Elizabeth Yeu, MD, to chat surgical pearls, patient management tactics, and whether premium IOLs are exacerbating vitreous opacities. Stick around at the end of the episode for some compelling conversation that our editors salvaged from the cutting room floor. 

This editorially independent podcast is supported with advertising.

As retina inches closer to a therapy that is safe and effective for the treatment of GA in the presence of dry AMD, the VBS Journal Club meets to review a pair of papers on a pair of pipeline treatments undergoing phase 3 evaluations. Aleksandra Rachitskaya, MD, is joined by Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD, to review phase 2/3 GATHER1 study, which is evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio). They also discuss a post hoc evaluation of the phase 2 FILLY study to determine which factors may be linked to the development of exudative AMD in some study patients after treatment with pegcetacoplan (Apellis), which is underdoing phase 3 investigation in the DERBY and OAKS studies. 

This editorially independent podcast is supported with advertising.

Safety will ultimately drive decision-making for patients with wet AMD. What are the latest safety data in the MERLIN, ARCHWAY, OPTIC, RGX-314, and TENAYA/LUCERNE trials? Moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), sift through the latest safety data to determine how concerns about safety could shape the future of wet AMD therapy. 

This editorially independent podcast is supported with advertising.

Perspectives regarding surgery for vitreous opacities (VOs) have shifted in the past several years. How have innovations in surgical instrumentation, visualization, and IOL technology changed how surgeons approach VOs? John Kitchens, MD, sits down with S.K. Steven Houston III, MD, and Christina Weng, MD, MBA, to hear their perspectives on the modern state of VOs, learn about their surgical tactics, and establish how they determine when to send patients to surgery.

This editorially independent podcast is supported with advertising.